Cantor Fitzgerald, L. P. Compass Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $90.6 Billion
- Q2 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 100,000 shares of CMPX stock, worth $416,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100,000
Previous 150,000
33.33%
Holding current value
$416,000
Previous $285,000
8.77%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding CMPX
# of Institutions
105Shares Held
101MCall Options Held
18.2KPut Options Held
2.51M-
Orbimed Advisors LLC San Diego, CA15.2MShares$63.3 Million1.41% of portfolio
-
Tang Capital Management LLC San Diego, CA13.5MShares$56.1 Million2.1% of portfolio
-
Blackstone Inc New York, NY10MShares$41.7 Million0.12% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.15MShares$29.7 Million0.64% of portfolio
-
Black Rock Inc. New York, NY6.61MShares$27.5 Million0.0% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $421M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...